Category Archives: Opioid Debate

Opioid Rx Limits Will Not Prevent Addiction

Will Strict Limits on Opioid Prescription Duration Prevent Addiction? Advocating for Evidence-Based Policymaking – Mallika L. Mundkur , MD, MPH, Adam J. Gordon , MD, MPH & Stefan G. Kertesz , MD, MSc – June 20, 2017

In 2016, the Centers for Disease Control and Prevention (CDC) issued the first national guideline in the United States regarding opioid prescribing for pain.

The guideline included the recommendation that patients treated for acute pain should receive opioids for no longer than 7 days, prompting at least five states to implement laws requiring prescribers not to exceed this threshold when providing initial opioid supplies.

The rapid conversion of this guideline into policy appears to reflect an underlying assumption that limiting initial opioid supplies will reduce opioid consumption, and thus addiction.   Continue reading

Better State Guidelines for Use of Opioid Analgesics

Guidelines for the Chronic Use of Opioid Analgesics from State Medical Boards Opioid Guidelines As Adopted April 2017_FINAL.pdf

Adopted as policy by the Federation of State Medical Boards April 2017

INTRODUCTION

In April 2015, the Federation of State Medical Boards (FSMB) Chair, J. Daniel Gifford, MD, FACP, appointed the Workgroup on FSMB’s Model Policy for the Use of Opioid Analgesics in the Treatment of Chronic Pain to review the current science for treating chronic pain with opioid analgesics and to revise the Model Policy as appropriate.

In updating its existing policy, the FSMB sought input from a diverse group of medical and policy stakeholders that ranged from experts in pain medicine and addiction to government officials and other thought leaders. 

This what the CDC should have done as well, but did not.  Continue reading

Response to FDA’s Request to Pull Opana Off Market

AIPM’s Response to FDA’s Request to Pull Opana ER Off Market – Academy of Integrative Pain Management Blog

On Thursday, June 8, the U.S. Food and Drug Administration “requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market,” the FDA said in a statement.

Apparently Opana ER, an extended release form of the opioid drug oxymorphone, was being crushed up and injected by people seeking to abuse it.

“After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse.”   Continue reading

Call lawyers Morgan & Morgan and tell your story

» call MORGAN & MORGAN ..tell your story… refer to chronic pain patient class action PHARMACIST STEVE June 19, 2017 by Steve Ariens

 Chronic Pain Patients – Call Now
Morgan & Morgan Lawyers
888-670-2630

Ask for the medical malpractice department.
Refer to chronic pain patient class action and tell your story. 
Continue reading

Will Pill Control “Fix” Our Problem?

Here is a video of Dr. Kertesz’ criticism of how the CDC guidelines have been turned into regulations in various health care settings:

Will Pill Control “Fix” Our Problem?: The Allure of Simple Solutions

Sound medical decision-making and
how propaganda is hurting otherwise stable patients

Three points:

  1. The CDC guideline was a serious response to a serious problem
  2. Emerging practices don’t respect it and people are being hurt
  3. How did we get here? Continue reading

The Role of Science in Addressing the Opioid Crisis

The Role of Science in Addressing the Opioid Crisis — NEJM – Nora D. Volkow, M.D., and Francis S. Collins, M.D., Ph.D. – May 31, 2017

Opioid misuse and addiction is an ongoing and rapidly evolving public health crisis, requiring innovative scientific solutions.

In response, and because no existing medication is ideal for every patient, the National Institutes of Health (NIH) is joining with private partners to launch an initiative in three scientific areas:

  1. developing better overdose-reversal and prevention interventions to reduce mortality, saving lives for future treatment and recovery;
  2. finding new, innovative medications and technologies to treat opioid addiction; and
  3. finding safe, effective, nonaddictive interventions to manage chronic pain.

Continue reading

Insufficient Evidence: How Opioid Deniers Spin Studies

Insufficient Evidence: How Opioid Deniers Spin Studies — Pain News Network – By Roger Chriss – April 2017

Researchers cannot and do not investigate if “opioids” work for “chronic pain.”

Good research is more narrowly focused, such as these clinical studies:

The results are equally specific. Continue reading

What the CDC is missing about the opiate crisis

What the CDC is missing about the nation’s opiate crisis – NY Daily News by Dr. Pawan Grover, M.d. May 16, 2017

The opiate crisis might have started with the overprescribing of pain medications but now it is a growing heroin crisis.

According to the CDC, 75% of heroin users started with prescription drugs.

This belief is the underlying foundation of the CDC’s efforts to reduce potential heroin addicts by limiting doctors to prescribe pain meds in the first place.

As an example, New Jersey is limiting pain prescriptions to a five-day supply. Essentially, the thinking is that to win the war on heroin, you need to win the war on prescription opiates.   Continue reading

Opioids, Evidence Based Medicine, and Public Policy

Opioids, Evidence Based Medicine, and Public Policy; The Art of Creating an Unnecessary Public Health Crisis – National Pain Report – by David Nagel, MD – May 25, 2017

Dr. Nagel demonstrates how low-quality evidence, like that used by the CDC for their guidelines, is normally not used clinically.

He compares how such poor evidence is handled in the case of the prostate-specific antigen (PSA) test (rejected) versus the CDC guidelines (recommended).

A few days ago I met with my doctor for my annual physical

We talked a great deal about the utility of the prostate specific antigen (PSA) test which has been used for a few decades to predict and, hopefully, prevent prostate cancer.  It came as a bit of a surprise to me that this widely touted test was no longer recommended.   Continue reading

Suspected opioid drug thefts persist at VA centers

Suspected drug thefts persist at VA centers | WISH-TV  – Hope Yen, AP – May 2017

Federal authorities are investigating dozens of new cases of possible opioid and other drug theft by employees at Veterans Affairs hospitals, a sign the problem isn’t going away as more prescriptions disappear.

Data obtained by The Associated Press show 36 criminal investigations opened by the VA inspector general’s office from Oct. 1 through May 19. It brings the total number of open criminal cases to 108 involving theft or unauthorized drug use

The numbers are an increase from a similar period in the previous year.   Continue reading